Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Plus Therapeutics (PSTV) Cost of Revenue (2016 - 2020)

Plus Therapeutics (PSTV) has disclosed Cost of Revenue for 10 consecutive years, with $104000.0 as the latest value for Q3 2020.

  • On a quarterly basis, Cost of Revenue rose 10.64% to $104000.0 in Q3 2020 year-over-year; TTM through Sep 2020 was $482000.0, a 36.93% increase, with the full-year FY2019 number at $468000.0, down 27.22% from a year prior.
  • Cost of Revenue was $104000.0 for Q3 2020 at Plus Therapeutics, down from $105000.0 in the prior quarter.
  • In the past five years, Cost of Revenue ranged from a high of $1.8 million in Q4 2016 to a low of -$1.7 million in Q4 2017.
  • A 5-year average of $385789.5 and a median of $118000.0 in 2018 define the central range for Cost of Revenue.
  • Peak YoY movement for Cost of Revenue: crashed 193.7% in 2017, then soared 246.81% in 2019.
  • Plus Therapeutics' Cost of Revenue stood at $1.8 million in 2016, then plummeted by 193.7% to -$1.7 million in 2017, then skyrocketed by 102.72% to $47000.0 in 2018, then skyrocketed by 246.81% to $163000.0 in 2019, then crashed by 36.2% to $104000.0 in 2020.
  • Per Business Quant, the three most recent readings for PSTV's Cost of Revenue are $104000.0 (Q3 2020), $105000.0 (Q2 2020), and $110000.0 (Q1 2020).